Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486944 | 0.94 | FAAH (0.47) | TDP1KMT2AMEN1CPB2L3MBTL1 | |
| SCHEMBL873537 | 0.94 | FAAH (0.47) | TDP1KMT2AMEN1CPB2L3MBTL1 | |
| SCHEMBL4904972 | 0.94 | FAAH (0.47) | TDP1KMT2AMEN1CPB2L3MBTL1 | |
| SCHEMBL11358682 | 0.94 | FAAH (0.47) | TDP1KMT2AMEN1CPB2L3MBTL1 | |
| SCHEMBL6309982 | 0.94 | FAAH (0.47) | TDP1KMT2AMEN1CPB2L3MBTL1 | |
| SCHEMBL1393272 | 0.94 | FAAH (0.47) | TDP1KMT2AMEN1CPB2L3MBTL1 | |
| SCHEMBL1393537 | 0.94 | FAAH (0.47) | TDP1KMT2AMEN1CPB2L3MBTL1 | |
| SCHEMBL21004865 | 0.92 | CYP4F2 (0.43) | TDP1KMT2AMEN1CPB2L3MBTL1 | |
| SCHEMBL7640286 | 0.92 | TDP1 (0.41) | TDP1KMT2AMEN1CPB2L3MBTL1 | |
| SCHEMBL15927750 | 0.92 | CYP4F2 (0.43) | TDP1KMT2AMEN1CPB2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412696-A1 | PROCESS FOR PRODUCTION OF 3-METHYL-CYCLOPENTADECENONE, PROCESS FOR PRODUCTION OF R/S-MUSCONE, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE MUSCONE | Doya, Masaharu (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20110172465-A1 | METHOD FOR PRODUCING 3-METHYL-CYCLOPENTADECENONES, METHOD FOR PRODUCING (R)- AND (S)- MUSCONE, AND METHOD FOR PRODUCING OPTICALLY ACTIVE MUSCONE | DOYA MASAHARU | 2011-07-14 | — | — | US | disclosed |
| EP-1156029-B1 | Derivatives of acetoacetic acid, their process of preparation and their use | BASF AG (DE) | 2003-06-18 | — | — | EP | disclosed |
| US-6515154-B2 | Acetoacetic acid derivatives, process for their preparation and their use | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-04 | — | — | US | disclosed |
| US-20010056195-A1 | Acetoacetic acid derivatives, process for their preparation and their use | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-27 | — | — | US | disclosed |
| EP-1156029-A1 | Derivatives of acetoacetic acid, their process of preparation and their use | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056195-A1 | Acetoacetic acid derivatives, process for their preparation and their use | ACMSD, MLYCD, HADHB | TDP1 3428/4885KMT2A 3842/4885MEN1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.